Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...

Novo Nordisk's stock has plummeted over 60%, while also arguably losing market share to Eli Lilly. Click here to find out why ...

Shares rallied Wednesday even after the drugmaker lowered its full-year guidance as alternative versions of its blockbuster ...

Novo Nordisk on Wednesday managed the unusual feat of seeing its stock price rise after reducing its earnings outlook. But that’s reflective of the tough times the Danish maker of Ozempic and ...

Novo Nordisk has reduced its sales and profits forecasts for 2025 due to lower-than-expected demand in the US for blockbuster weight loss and diabetes drugs, though shares in the company were ...

One day after WeightWatchers said that it would file for bankruptcy, weight-loss drug giant Novo Nordisk’s outlook is brightening. Novo Nordisk, the Danish company that produces the semaglutide ...

Novo Nordisk stock (DK:NOVO.B) (NVO) rose 2% in Copenhagen trade. But the stock is still down about 28% this year and less than half the value of its peak last June. The company said its first ...

LONDON/COPENHAGEN, May 7 (Reuters) - Obesity drugmaker Novo Nordisk's CFO said on Wednesday he was sceptical that U.S. President Donald Trump's executive order to reduce the time it takes to ...

Booming sales of Wegovy helped to make Novo the most valuable listed company in Europe ... Jorgensen said on a call with journalists. Novo Nordisk said first-quarter sales of Wegovy were 17. ...

Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for Novo Nordisk imply an improvement in the company's underlying business. Investors should show their ...

Novo Nordisk shares jumped following stronger-than-expected first-quarter earnings, despite the company lowering its growth outlook for 2025 amid intensifying competition in the weight-loss drug ...

Novo Nordisk NOVO.B-0.65%decrease; red down pointing triangle shares rallied Wednesday as investors breathed a sigh of relief after first-quarter earnings beat expectations and the company’s ...